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Long-term survival of arteriovenous fistulas in home hemodial-
ysis patients.
Background. We report the outcome of arteriovenous (AV)
fistulas created and managed by a multidisciplinary team in pa-
tients on hemodialysis (HD) over 20 years.
Methods. We analyzed 432 AV fistulas in 301 home HD pa-
tients (12% diabetic; median age 47 years) followed for up to
161 months. Observed end points were spontaneous or surgical
AV fistula closure, or construction of a new vascular anastomo-
sis. Survival was analyzed for first and second AV fistulas and
predictors of outcome for first AV fistulas.
Results. One vascular surgeon constructed 58% of AV fistu-
las. Three hundred sixty-seven AV fistulas were in the forearm,
64 at or above the elbow, and 1 in the thigh. Four hundred four-
teen AV fistulas used in situ vessels, and 18 were autografts.
Two hundred thirty-one anastomoses were side-to-side. Only
five grafts were placed during this time. There were 131 second
and subsequent AV fistulas in 76 patients, 79 (60%) of which
required primary construction, and 52 used arterialized vessels
from a previous AV fistula. The median time from formation to
use for first and second AV fistula, respectively, was 2.39 (SE
0.35) and 3.2 (SE 1.9) months. Assisted survival from first use
for first AV fistula was 90% at 1 year, 66% at 5 years, 84% at 1
year, and 72% at 2 years for second AV fistula. AV fistula sur-
vival from creation was superior for side-to-side anastomoses
(P < 0.0001) and in men (P = 0.05).
Conclusion. A multidisciplinary approach has been success-
ful in providing durable AV fistulas for home HD for >95% of
consecutive patients entering our program.
Maintenance hemodialysis (HD) is dependent on
durable vascular access. The development of the Quin-
ton Scribner arteriovenous shunt made long-term HD
possible [1]. Since 1966, the arteriovenous (AV) fistula,
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developed by Brescia and Cimino [2], has provided the
best vascular access with a low risk of infection and im-
proved convenience for patients. As early as 1976, despite
the obvious advantages of the AV fistula, many nephrolo-
gists and surgeons felt compelled to use prosthetic devices
[3]. In comparison to AV grafts, the AV fistula has a much
lower risk of thrombosis [4].
Ideal vascular access delivers adequate flow rate over
periods of years with a low rate of complications [5, 6]. AV
fistulas have the best long-term patency rates, need fewer
interventions [6], and are associated with better patient
survival [7] than other forms of vascular access. While
in most other countries the AV fistula is preferred al-
most exclusively, the National Kidney Foundation DOQI
Clinical Practice Guidelines for Vascular Access recom-
mend that an AV fistula should be the primary vascular
access in 50% of patients, and that 40% of prevalent pa-
tients should use an AV fistula [5]. K-DOQI also recom-
mends a thrombosis rate of 0.5/patient-year for AV grafts,
and 0.25/patient-year for AV fistulas as acceptable [5].
No recommendations are made for acceptable AV fistula
survival.
The proportion of HD patients who use an AV fistula
varies throughout the world, from 24% in the United
States [8], 62% to 85% in Europe [8–10], and 81% and
63% in Australia and New Zealand, respectively [11]. The
possible reasons for these differences in AV fistula use
are both patient and physician specific. Late presenta-
tion of patients, and an immediate need for useable vas-
cular access, precludes the early use of AV fistula. Older
patients and those with diabetes are said to have “inad-
equate veins,” and AV fistula formation may be more
difficult. Many vascular surgeons understandably wish to
use new technology, but many lack understanding of the
significance of the vascular access procedure for the long-
term care of patients with end-stage renal failure (ESRF).
The manufacturers of prosthetic devices may influence
practice, and some recently trained nephrologists and sur-
geons are not aware of the value of an AV fistula to the
patient requiring long-term HD.
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We currently provide a regional nephrology service for
480,000 people covering 64,682 km2 of sparsely populated
land. All patients requiring treatment of ESRF referred
to our unit were trained for home dialysis—home HD
alone until 1979, and after this, CAPD as well, dependent
on patient choice [12]. There is an active renal transplant
program with 63% of all current ESRF patients having
a functioning renal transplant. Until 1990, HD was the
predominant treatment modality.
The aim of this study was to analyze the outcome of
AV fistulas in an exclusively homebased HD program.
We were able to carry out the present study because we
have had a unit policy of avoiding polytetrafluoroethy-
lene (PTFE) grafts and permanent vascular catheters in
favor of AV fistulas, and have been supported by dedi-
cated surgeons involved in all other surgical aspects of
the patients’ care, including transplantation.
METHODS
Patients
All patients who started maintenance HD as their first
form of treatment for ESRF in our unit between Septem-
ber 1, 1979, and August 31, 1999, were studied. The de-
cision to choose HD was based on a combination of the
patient’ choice, after education, and nephrologist and vas-
cular surgeon advice. Patients with serious comorbidities
expected to have a poor prognosis were often advised
to opt for continuous ambulatory peritoneal dialysis
(CAPD), given our lack of center dialysis facilities for
maintenance HD. Only rarely were concerns regarding
the provision of vascular access a cause for recommend-
ing CAPD. A retrospective review of vascular access data
was carried out for the period from 1979 to mid-1985.
From mid-1985 onward, all data were entered prospec-
tively into a computerized clinical database, ProtonTM
(Clinical Computing, Ltd., London, UK). Data obtained
from the clinical database, case records, and operation
notes were entered into an Microsoft Excel spreadsheet
for analysis. The cause of ESRF and comorbidities at the
start of dialysis were recorded using the definitions of
the Australian and New Zealand Dialysis and Transplant
Registry (ANZDATA) [13]. During the last 10 years of
the study the number of new ESRF patients per year rose
from 41 to 61 per million population, the average age was
54 years, and 15% had diabetes mellitus as their cause of
ESRF.
Hemodialysis
Until August 1998, all training and home dialysis was
undertaken with nonvolumetric single-patient dialysis
machines, hollow fiber Cuprophan dialyzers (0.8 m2),
and acetate-based dialysate. Since then, there has been a
change to polysulphone dialyzers (1.0 or 1.3 m2), and a
gradual change to volumetric machines and bicarbonate
dialysate. Since 1983, there has been no reuse of dialyzers
or bloodlines. The blood pump speed was 200 mL/min,
and dialysate flow rate 500 mL/min. Patients dialyzed for
5 hours 4 times per week during training. Home HD was
for 7 hours 3 times per week (range 10 to 36 hours per
week). All patients were trained for nocturnal dialysis,
and approximately one third of patients chose to dialyze
overnight. The unit policy does not permit unattended
home HD.
Vascular access methods
An AV fistula was defined as one constructed from
in situ vessels or a venous autograft. Patients with pro-
gressive renal impairment likely to require dialysis were
referred to the vascular surgeon and senior dialysis clini-
cian for the planning of an AV fistula. Patients were seen
jointly and the side, site, type of anastomosis, and timing
of AV fistula creation decided. In only a few cases were
venography or Doppler ultrasonography studies of the
upper limb carried out. Patients were instructed not to
allow venipuncture of the chosen arm.
In the early part of the series fistula operations were
performed under general anesthesia, but this was subse-
quently replaced by almost exclusive use of local anes-
thetic infiltration with a 50:50 mixture of 1% lignocaine
and 0.5% Marcaine with adrenaline. Where possible, an
AV fistula was created in the nondominant forearm with
a side-to-side vascular anastomosis between the radial
artery and the ventral tributary of the cephalic vein. The
distal vein was generally not ligated primarily. If the ven-
tral tributary was inadequate, the dorsal tributary was
mobilized and usually divided and anastomosed end-to-
side to the radial artery. Venous hypertension distal to
the vascular anastomosis was rare and easily managed
by ligating distal venous channels and attending to proxi-
mal venous stenoses if present. The latter were generally
managed by open repair with a vein patch or interpo-
sition graft. If it was not possible to form a radial AV
fistula in the nondominant forearm, the next sites for
vascular access, in order of preference, were dominant
forearm, nondominant arm, at or above the elbow (usu-
ally brachio-cephalic), and dominant arm. At each site
the type of vascular anastomosis was decided on a case-
by-case basis.
Since the mid 1980s patients received aspirin 300 mg
orally and flucloxacillin 1 g intravenously (or ery-
thromycin for penicillin-allergic patients) preoperatively.
Antihypertensive medication was routinely withheld on
the day of surgery. Patients were taught to feel for the AV
fistula thrill, and to report any significant change or ab-
sence; or redness, swelling, or pain in the AV fistula arm.
They were advised to use a sling for two days after surgery.
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Fig. 1. Type of vascular anastomosis for first and subsequent arteriove-
nous (AV) fistulas.
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Fig. 2. Survival of first () and second () arteriovenous (AV) fistulas
from first use. End points for survival analysis were spontaneous or sur-
gical AV fistula closure, or construction of a new vascular anastomosis.
The survival for the first AV fistula was 90% at 1 year, 80% at 2 years,
and 66% at 5 years, and for the second AV fistula, 84% at 1 year and
72% at 2 years.
No specific instructions were given regarding hand
exercises. No protocol for systematic fistula surveillance
was used.
Assessment of the AV fistula before first cannulation
was performed by the senior dialysis clinician (ALB),
who determined the timing and number, size, and type
of initial cannulas (steel or plastic). He almost always
performed the initial and subsequent cannulation until
the AV fistula was considered adequate for the other
dialysis staff to continue cannulation. This period could
be from days to weeks, and training for home dialysis
did not usually start until after this time. Most patients
were taught the “ladder” technique of cannulation. Oc-
casionally the “button hole” technique was used for small
AV fistulas. During home dialysis training patients were
taught to self-cannulate using 15G stainless steel needles
with a backeye. A local anesthetic was used during the
training period, and the majority of patients continued
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Fig. 3. Survival of first () and second () arteriovenous (AV) fistulas
from creation. End points for survival analysis were spontaneous or sur-
gical AV fistula closure, or construction of a new vascular anastomosis.
The survival for first fistula was 79% at 1 year, 72% at 2 years, and 59%
at 5 years, and for second fistula 65% at 1 year, 52% at 2 years, and 24%
at 5 years.
this practice on home HD. In <1% of cases (e.g., im-
paired vision or manual disability, pediatric patients), a
relative was taught to cannulate the fistula. Aspirin was
sometimes prescribed for patients with second and sub-
sequent fistulas if there had been an early failure with the
first AV fistula. There was no systematic long-term use of
anti-platelet agents with the intention of prolonging fis-
tula patency duration. Less than 5% of patients required
antihypertensive medication after starting hemodialysis
[12].
Statistical analysis
The following end points were counted as fistula fail-
ure: spontaneous or surgical AV fistula closure, construc-
tion of a new vascular anastomosis, AV fistula no longer
useable for dialysis, or change to alternative vascular
access (e.g., vascular catheter). Censoring events were
transplantation, death, or the end of the study. Survival
was analyzed for first and second AV fistulas from both
creation and first use. Predictors of outcome from cre-
ation were studied for first AV fistula only. For time un-
til use, fistula failure counted as an additional censoring
event, that is, the median time given is for those whose
fistulas continued to function.
The statistical package BMDP (Chicago, IL, USA) [14]
was used for analyses. Survival analysis was carried out
using program 1L (Kaplan-Meier survival estimates). The
Tarone-Ware statistic [14] was used for comparison of
groups in program 1L. This is a compromise between log-
rank and Breslow statistics. Figures 2 and 3 show survival
only up to the last event. For time from creation of a
fistula, the last censored observation was at 127 months
for the first fistula, and 109 months for the second. For
time from use, the maxima were 126 and 107 months.
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Table 1. Patients studied (N = 301)
Age in years—median (range) 47 (6–77)
Gender—male % 64
Ethnicity %
Caucasian 89
Maori/Pacific Islander 7
Other 4
Cause of ESRF %
Polycystic kidney disease 10
Diabetes 12
Glomerulonephritis 31
Renal vascular disease 11
Reflux nephropathy 9
Obstructive uropathy 2
Other causes 25
Smoker %
Never 49
Previous 28
Current 23
On antihypertensive drugs when AVF constructed % 75
Peripheral vascular disease % 11
Table 2. Corrective procedures carried out on arteriovenous fistulas
Procedure Number
Surgical thrombectomy 33
Tying off of collateral vessels 22
Insertion of PTFE “bridge” conduit 13
Repair aneurysm 7 (5 true, 2 false)
Angioplasty 7
Other procedure (e.g., thrombolysis, 14
reposition vessels)
Total 96
RESULTS
Patients
During the period of the study period a total of 409 pa-
tients began renal replacement therapy. The study group
comprised 301 patients, predominantly Caucasian with
low rates of diabetic nephropathy (Table 1). Comorbidi-
ties relevant to vascular access survival are shown in
Table 1. After starting HD the patients were followed
for a median of 21 (range <1 to 161) months.
Vascular access
During the study period there were 485 permanent vas-
cular access procedures performed. Those involving pros-
theses, two PTFE, and three Omniflow grafts, and 48 first
AV fistulas not used for dialysis during the study period
were excluded from the analysis. Thus, we studied 432
AV fistulas, 301 of which were first AV fistulas, and 131
subsequent AV fistulas (76 second, 32 third, 23 fourth to
eighth). Seventy-six patients had 131 subsequent AV fis-
tulas constructed, 79 (60%) of which required primary
construction, and 52 (40%) used arterialized veins from
previous AV fistulas. One vascular surgeon constructed
58% of the AV fistulas. The remainder of the AV fistulas
was constructed by other vascular surgeons (20%) or by
supervised surgical trainees (16%), and in 6% of cases the
surgeon could not be identified. Of the 301 first AV fis-
tulas, 287 (95%) were in the forearm, and 14 (5%) in the
arm, at or above the elbow. Of the 131 subsequent AV fis-
tulas, 80 (61%) were in the forearm, 50 (39%) in the arm,
and one in the thigh. A side-to-side vascular anastomosis
was created in 67% of first AV fistulas, while there was no
predominant anastomosis used for subsequent AV fistu-
las (Fig. 1). After initial formation, 63 AV fistulas (15%)
required 96 procedures to enhance or maintain patency
and performance (Table 2). During this study 75% of
these home HD patients required only one AV fistula. At
the end of the study 144 (48%) of the patients were alive
with a renal transplant, 36 (12%) remained on hemodial-
ysis, 43 (14%) had changed to another dialysis modality,
65 (22%) had died, 7 had transferred to the care of an-
other unit, 4 had recovered renal function, and 2 were
dialyzing with vascular catheters.
Arteriovenous fistula survival
First and second AV fistulas, respectively, were first
used for HD a median of 2.39 (SE 0.35) and 3.2 (SE 1.9)
months, respectively, after creation. Treatment for ESRF
after failure of the first AV fistula was with peritoneal
dialysis or a vascular catheter, if necessary. The survival
from use for first and second AV fistula is shown in Figure
2, and overall survival in Figure 3. Analysis of first AV fis-
tula survival was compared over three time periods, 1979
to mid-1985 (retrospective period, N = 88), mid 1985 to
1992 (N = 107), 1993 to 1999 (N = 106). There was no
difference in survival from first use (P = 0.81), but sur-
vival from creation did differ (P = 0.05) because the first
period had more early failures (Table 3). The causes of
AV fistula failure are shown in Table 4. It is often difficult
to be certain of the cause of fistula failure. The number of
AV fistula failures listed as “unknown cause” were seen
throughout the study period, not just in the retrospective
period. AV fistula survival from creation was superior for
side-to-side anastomoses (P = 0.0001) and in men (P =
0.05). Side or site of AV fistula, operating surgeon, or
other patient factors did not predict outcome (Table 5).
Rate of procedures and subsequent fistulas
Patients were observed for a total of 744.8 person-
years, that is, from fistula creation until one of the end
points such as transplantation or death or end of study.
In that time 131 subsequent fistulas were created (in 76
patients), and 96 corrective procedures were carried out,
giving a combined rate of 0.30 per patient-year.
DISCUSSION
We have shown that it is possible to provide durable
AV fistulas with excellent patency rates for almost all of
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Table 3. Early failure and survival at 1, 2, and 5 years from creation for AV fistulas
% Survival (95% CI)
Fistula Period % Failing in first month (95% CI) 1 year 2 years 5 years
First 1979 to mid1985 18 (10, 26) 73 (64, 83) 65 (53, 76) 53 (38, 68)
Mid 1985 to 1992 7 (2, 11) 82 (74, 90) 75 (66, 84) 62 (48, 77)
1993 to 1999 4 (0, 7) 82 (74, 90) 76 (67, 86) 67 (54, 80)
Combined 9 (6, 12) 79 (75, 90) 72 (67, 78) 59 (48, 69)
Second Combined 18 (10, 27) 65 (54, 76) 52 (39, 64) 24 (10, 38)
Table 4. Reasons for AV fistula failure
3rd and
1st AV 2nd AV subsequent
End point fistula fistula AV fistula
Reanastomosis 7 1 2
Thrombectomy and reanastomosis 7 0 0
Surgical closure 4 1 1
Thrombosisa 31 25 10
Patent but not usable for dialysis 14 4 5
Excision of fistula 0 0 2
Unknown cause of failure 19 4 7
Censored or end of study 219 41 28
Total 301 76 55
aClinical assessment in majority.
Table 5. Predictors of survival for first AV fistula
Predictor P (Tarone Ware)
Categorical variables
Anastomosis (side-to-side) 0.0001
Gender (male) 0.05
Cause of ESRF (diabetes, polycystic, other) 0.73
Side of AV fistula 0.44
Site of AV fistula (forearm/upper arm) 0.58
Operating surgeon 0.44
Smoking history 0.94
Current treatment for hypertension 0.80
Peripheral vascular disease 0.14
Continuous variablesa
Age 0.84
Systolic blood pressure 0.99
Diastolic blood pressure 0.19
Hemoglobin 0.27
aThe patients were divided into three groups for each variable (bottom third,
middle third, top third).
a group of patients on home HD. Only 5 (1%) of 485 pri-
mary operative procedures for permanent vascular access
in our patients involved prostheses. Of the 96 subsequent
operative procedures that were necessary to maintain,
or enhance, AV fistula function, 13 (14%) utilized PTFE
bridge grafts. Our results are noteworthy because the pa-
tients carried out their own vascular access cannulation
and were unsupervised during dialysis. Although our pa-
tient group was younger and had a lower rate of diabetes
mellitus than current incident patients in many countries,
we believe the factors that have contributed to our re-
sults are relevant to the provision of long-term vascular
access for all patients treated with HD. A recent report on
vascular access in 748 consecutive center dialysis patients
closely mirrors our experience, in spite of the patients be-
ing about 10 years older and more likely to have diabetic
nephropathy [15].
During this study 75% of these home HD patients re-
quired only one AV fistula. This high prevalence rate
for AV fistulas may have been achieved by offering
peritoneal rather than HD to sicker, older patients at
increased risk of vascular access failure. In most cases,
however, the feasibility of providing vascular access was
not a factor in the patient’s choice of treatment modal-
ity. A recent national study showed that our current ac-
ceptance rates for treatment of ESRF are the same as
those of other dialysis units in New Zealand when ad-
justed for age, gender, comorbidity, and activities of daily
living scores [16].
The prevalence of AV fistulas in dialysis patients varies
throughout the world [8, 9–11, 17] and within countries
[8, 18]. The highest rates of AV fistula use are in Japan,
Europe [8, 18], and Australasia [11] (60% to 90%), and
the lowest rates are in the United States (20% to 24%) [8,
17]. A number of studies have identified certain patient
characteristics, such as age, gender, obesity, presence of
diabetes, and race as predictors of the prevalence of AV
fistula use [8, 19, 20]. Nevertheless, the differences in
prevalence between units in the United States are not ex-
plained by differences in demographic and clinical factors
[8, 18, 20–22]. The critical factor that appears to determine
the rate of AV fistula use is the degree of involvement
of the vascular access surgeon, and his/her understand-
ing of the overall management of patients with ESRF.
Quality improvement programs involving nephrology
and surgical staff [23], and the routine use of preoperative
noninvasive assessment of upper limb vessels [24] have
been shown to increase the prevalence of AV fistulas. The
Dialysis Outcomes and Practice Patterns Study (DOPPS)
identified unit and staff preferences as being more impor-
tant determinants of AV fistula use than patient charac-
teristics or preferences [8]. Similar suggestions have been
made by others commenting on the low rates of AV fistula
use in the United States [18, 23, 25].
As expected from the results of other studies, we have
shown that AV fistulas have superior patency rates to
those reported for PTFE grafts [5, 15, 26]. Studies of
AV fistulas have reported survival in various ways, usu-
ally from the time of creation to functional failure. The
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definitions for primary, or unassisted, and secondary, or
assisted, survival also differ, although there has been a
recent attempt to standardize these classifications [17].
Our definition of patency end point (see Methods) most
closely matches the K-DOQI definition of secondary sur-
vival. We found survivals from first use for first AV fistula
of 90% at 1 year and 66% at 5 years, and 84% at 1 year and
72% at 2 years for second AV fistula. These results are
to be compared with reports of primary patency rates of
53% to 75% at one year and 50% to 65% at two years [15,
26, 27], and secondary patency rates of 56% to 79% at one
year, 68% at two years, and 30% at 5 years from other
units treating center HD patients [28, 29]. The DOPPS
Study reported one-year primary patency rates for AV
fistulas of 68% in the United States and 83% in Europe
[8]. The Catalan Registry reported a median patency rate
of 3.5 years in a questionnaire on 2638 patients [10]. An
important finding in our study is the low rate of early
AV fistula failure during the first postoperative month of
9% for first fistula (4% during later period of study), and
18% for second fistula (Fig. 3, Table 3), which we think
results from the early integrated planning of vascular ac-
cess procedures. Other studies report early failure rates
of 13% to 53% for AV fistulae [27, 28, 30]. The rate of
all subsequent vascular access procedures for the study
group was low at 0.3 per patient-year during the 20-year
period of our study, with most hospital admissions being
for 1 to 2 days. This total surgical intervention rate can
be compared with the experience of Konner et al, who
reported thrombosis rates for first AV fistula of 0.03 per
patient-year for nondiabetic patients [15]. A study in a
large United States dialysis unit found an access-related
hospitalization rate of 1.74 per patient-year for dialysis
patients [31]. The authors noted that greater attention to
timely placement of vascular access could result in re-
duced interventions and cost savings.
Two studies with conflicting results have examined
whether the operating surgeon predicts AV fistula sur-
vival [27, 30]. We did not find that the operating sur-
geon was a predictor of AV fistula survival, but this was
to be expected as the majority of AV fistulas were cre-
ated by one surgeon (JBM), or by surgical trainees under
his direct supervision. We found that the only predic-
tors of first AV fistula survival were the type of vascu-
lar anastomosis (side-to-side) and male gender (Table 5).
It is likely that a side-to-side anastomosis was used
preferentially in those patients with the most favorable
venous anatomy. Many surgeons now prefer arterial-side-
to-vein-end anastomoses and are able to achieve low
early failure rates and long-term patency [15, 32]. Others
have found either a small effect [15], or no effect of gender
on AV fistula survival [27, 28]. A number of studies have
reported that older age [9, 10, 27, 28, 30, 33] and diabetes
[10, 27, 28] are associated with reduced AV fistula patency
rates. Age and diabetes as the cause of renal failure were
not significant predictors of outcome in our study, but our
patient population was relatively young and few patients
had diabetes mellitus in comparison with other studies.
We think that a dedicated surgical service and expert
training in self care of vascular access are the most im-
portant factors in determining the outcome of AV fistulas.
Systematic multidisciplinary assessment has been recom-
mended as necessary to ensure continued patency of AV
fistulas [18]. Although our patients were taught to report
any systematic increase in venous pressure during dial-
ysis, we did not use a formal protocol for measurement
of fistula flow rates and still obtained excellent results, as
did Konner et al [15].
CONCLUSION
The AV fistula is the preferred form of vascular ac-
cess for HD. Achieving a high prevalence of AV fistulas
for HD patients requires a clear unit policy and the joint
involvement in the planning of all vascular access proce-
dures of surgeons, dialysis clinicians, and nephrologists.
Such planning should be individualized and favor per-
manency, not expediency, to reduce early failure rates.
Prolonged patency rates are dependent on skilled initial
use of AV fistulas by dialysis clinicians and, for home
HD, subsequent successful training of patients in self-
cannulation.
Reprint requests to Associate Professor K. L. Lynn, Department of
Nephrology, Christchurch Hospital, Private Bag 4710 Christchurch 8020
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